Postdoctoral fellow
Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts
Elena Maroto Martín, PhD, is a postdoctoral fellow at Dana-Farber Cancer Institute and a research collaborator at the Massachusetts Institute of Technology (MIT), where she contributes to translational oncology projects. She earned her PhD in Biomedical Research from the Complutense University of Madrid, where she developed novel CAR-NK therapies for relapsed multiple myeloma. Her doctoral work uncovered a combination approach that improves tumor sensitivity to CAR-based immunotherapy, with promising implications in blood cancers.
At Dana-Farber, Dr. Maroto focuses on identifying novel therapeutic targets in multiple myeloma to advance CAR-based immunotherapies. Her work has led to the development of next-generation CAR T cells targeting both surface and intracellular proteins, including MZB1—an endoplasmic reticulum protein presented on MHC class I molecules. At MIT, she contributes to the development of antibody-drug conjugates (ADCs) from molecular design to validation in preclinical models.
Dr. Maroto has presented her research at international conferences and received several awards throughout her career. She is passionate about translating basic discoveries into innovative therapeutic strategies for patients with hematologic cancers. Her international experience, which includes research stays in Spain, Slovenia, and the United States, reflects a strong commitment to collaborative science and translational oncology.
Disclosure information not submitted.
(OA-10) MZB1-Directed HLA-Dependent CAR T Cells for Targeting B-Cell Malignancies
Wednesday, September 17, 2025
11:20 - 11:30 East Coast USA Time